In the phase 3 POETYK PSO-1 multinational, multicenter, randomized, double-blind, placebo- and active-comparator-controlled 52-week clinical trial of deucravacitinib (Sotyktu), results showed that it was well tolerated and demonstrated efficacy that was superior to placebo and apremilast (Otezla). Read the full article from the January 2023 JAAD edition here:Read the Full JAAD Article
Reference: Armstrong AW, Gooderham M, Warren RB, et al. Deucravacitinib versus placebo and apremilast in moderate to severe plaque psoriasis: Efficacy and safety results from the 52-week, randomized, double-blinded, placebo-controlled phase 3 POETYK PSO-1 trial. J Am Acad Dermatol. 2023;88(1):29-39.
Last modified on April 19th, 2023 at 9:08 am